13d agoThe FlyBULLISH 76Product/PR
Archived explainer. For the current picture see today's ARWR page.
Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 31, 2026 at 6:41 AM ET · reviewed against 4 wire stories
ARROWHEAD PHARMACEUT (ARWR) is drawing unusual attention today. Our newswire has captured 4 stories on ARWR across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 75/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ARWR stock is moving today
Arrowhead Pharmaceuticals (ARWR) shares are moving following the release of positive Phase 3 clinical trial results for its drug candidate plozasiran. The SHASTA-3 and SHASTA-4 studies met primary endpoints, showing a 78% reduction in acute pancreatitis events in patients with severe hypertriglyceridemia. These findings, along with a reported 79% to 81% reduction in triglyceride levels, have generated optimism about the drug’s potential regulatory filing by year-end 2026.
What Happened
Arrowhead Pharmaceuticals announced that its Phase 3 SHASTA-3 and SHASTA-4 trials for plozasiran achieved significant results. The drug reduced triglyceride levels by approximately 80% and cut pancreatitis events by 78% in patients with severe hypertriglyceridemia. Over 90% of participants reached triglyceride levels below 500 mg/dL at Month 12. These outcomes were presented at the European Society of Cardiology Congress and were also highlighted in a recent filing timeline. Additionally, Arrowhead’s REDEMPLO received approval in Germany for Familial Chylomicronemia Syndrome, marking a key European milestone.
What The Data Shows
Over the last eight trading sessions, ARWR stock has declined by 5.0%, moving from $89.41 to $84.91. Recent insider transactions include two sales totaling $1.2 million, with the most recent filing on August 20. No insider purchases were reported in the last 90 days. Over the same period, one congressional trade was disclosed, with no purchases. Retail traders on social platforms are discussing the drug’s potential, though no specific price targets are cited. The stock’s 30-day average sentiment score is 63 out of 100, improving to 70 in the last seven days.
What To Watch
Arrowhead Pharmaceuticals is expected to file for regulatory approval of plozasiran by year-end 2026. Investors should monitor the company’s progress in this timeline, along with any additional data presentations or regulatory updates. Coverage breadth is also a factor to watch, as four stories from four sources have appeared in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARWR by the numbers
7 sessions: -6.13%Coverage: 4 stories / 4 sourcesAI sentiment: 75/100 (bullish)Mkt cap: $12.0B52w: $21.61 to $95.49
The headlines behind the move
13d agoSeeking AlphaBULLISH 76Product/PR
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
Arrowhead (ARWR) reports Phase 3 plozasiran cut triglycerides ~80% and pancreatitis events 78% in severe hypertriglyceridemia—see filing timeline.
13d agoStockTitanBULLISH 73Product/PR
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
TG fell 79% and 81% in Phase 3 studies; over 90% reached TG levels below 500 mg/dL at Month 12, and an FDA filing is planned by year-end 2026.
15d agoYahoo TopBULLISH 73Product/PR
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany. Following European Commission authorization in June 2026, the drug is now listed in the Lauer-Taxe database for prescribing and reimbursement. Unlike existing options requiring genetic confirmation, REDEMPLO […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ARWR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ARWR move explainers: 2026-09-08 · 2026-08-31